Emergent Biosolutions Inc Total Liabilities
Emergent Biosolutions Inc total liabilities. Based on the latest financial reports, Emergent Biosolutions Inc (EBS) has total liabilities worth $775.40 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Emergent Biosolutions Inc (EBS) asset resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Emergent Biosolutions Inc (2001–2025)
Total liabilities of Emergent Biosolutions Inc from 2001 to 2025. This chart illustrates how Emergent Biosolutions Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Emergent Biosolutions Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Emergent Biosolutions Inc Competitors by Total Liabilities
The table below lists competitors of Emergent Biosolutions Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Empire Energy Group Ltd
AU:EEG
|
Australia | AU$30.56 Million |
|
Grupa Azoty Zaklady Azotowe Pulawy SA
WAR:ZAP
|
Poland | zł4.11 Billion |
|
Instabank ASA
OL:INSTA
|
Norway | Nkr8.11 Billion |
|
Vestland Berhad
KLSE:0273
|
Malaysia | RM774.33 Million |
|
Dabaco
VN:DBC
|
Vietnam | ₫7.91 Trillion |
|
Shanghai Dragonnet Tech
SHE:300245
|
China | CN¥254.08 Million |
|
Fourlis Holdings S.A.
AT:FOYRK
|
Greece | €693.83 Million |
|
Stellar V Capital Corp. Unit
NASDAQ:SVCCU
|
USA | $5.37 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Emergent Biosolutions Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Emergent Biosolutions Inc balance sheet assets.
Liquidity & Leverage Metrics
Emergent Biosolutions Inc Total Liabilities Ratios Explained
Emergent Biosolutions Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Emergent Biosolutions Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Emergent Biosolutions Inc (2001–2025)
The table below shows the annual total liabilities of Emergent Biosolutions Inc from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $796.00 Million | -12.23% |
| 2024-12-31 | $906.90 Million | -22.74% |
| 2023-12-31 | $1.17 Billion | -34.00% |
| 2022-12-31 | $1.78 Billion | +32.12% |
| 2021-12-31 | $1.35 Billion | -6.27% |
| 2020-12-31 | $1.44 Billion | +15.93% |
| 2019-12-31 | $1.24 Billion | +1.67% |
| 2018-12-31 | $1.22 Billion | +671.88% |
| 2017-12-31 | $157.86 Million | -57.78% |
| 2016-12-31 | $373.91 Million | -2.52% |
| 2015-12-31 | $383.57 Million | -2.16% |
| 2014-12-31 | $392.06 Million | +185.21% |
| 2013-12-31 | $137.47 Million | +12.58% |
| 2012-12-31 | $122.10 Million | -6.17% |
| 2011-12-31 | $130.14 Million | +2.67% |
| 2010-12-31 | $126.76 Million | +25.66% |
| 2009-12-31 | $100.87 Million | +10.32% |
| 2008-12-31 | $91.44 Million | -10.66% |
| 2007-12-31 | $102.35 Million | +2.57% |
| 2006-12-31 | $99.78 Million | +145.80% |
| 2005-12-31 | $40.59 Million | -11.95% |
| 2004-12-31 | $46.11 Million | +147.42% |
| 2002-12-31 | $18.64 Million | -67.71% |
| 2001-12-31 | $57.72 Million | -- |
About Emergent Biosolutions Inc
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States, Canada, and internationally. It operates through Commercial Products, MCM Products, and All Other Revenues segments. The company offers ACAM2000, a smallpox and mpox vaccine; Anthrax Immune Globulin Intrav… Read more